- Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF）
- Senju has developed and obtained approval for a BAC-free formulation of Aibeta® combination eye drops（PDF）
- Announcement of Licensing Agreement with Brill International（PDF）
- Launch and Distribution of “MIEr for BeelineMED”（PDF）
- Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132（PDF）
- Launch and Distribution of “MIEr for ImageFS”（PDF）
- Launch of Distribution of Software for Dry-eye Analysis（PDF）
- Acquisition of Marketing Approval for “ Mytear LUMIFY”（PDF）
- Launch of Distribution of RET-700（PDF）
- Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132（PDF）
- Notice of Orphan Drug Designation for SJP-0008 as a Treatment of Central Retinal Artery Occlusion（PDF）
- Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion（PDF）
- Launch and Distribution of “MIEr for NAVIS”（PDF）